Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as an injectable formulation for subcutaneous use. It is employed to control excess growth hormone secretion in acromegaly and to manage hormone‑related symptoms of gastroenteropancreatic neuroendocrine tumors in adult patients.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mytolac (lanreotide acetate) acts on somatostatin receptors to regulate hormone‑secreting disorders. - Acromegaly: reduces elevated growth hormone levels and associated clinical features. - Gastroenteropancreatic neuroendocrine tumors: controls tumor‑related hormone secretion and alleviates related symptoms. - Hormone hypersecretion disorders: helps normalize abnormal endocrine hormone release.

Adverse reactions may occur with lanreotide therapy and are reported across clinical use.

Common Side Effects: - Injection site pain or erythema - Nausea - Diarrhoea - Abdominal pain - Headache - Hyperglycaemia

Serious or Rare Side Effects: - Gallstone formation or biliary colic - Acute pancreatitis - Severe hyperglycaemia or new‑onset diabetes - Anaphylactic or severe allergic reactions - Cardiovascular events such as arrhythmia - Pituitary apoplexy (rare)

Before initiating therapy, clinicians should consider several safety aspects. - Blood glucose monitoring: assess for hyperglycaemia, especially in diabetic patients. - Gallbladder evaluation: avoid in patients with known gallstones or biliary disease. - Pancreatic function: monitor for signs of pancreatitis. - Cardiac assessment: use caution in patients with existing cardiac conditions. - Renal/hepatic impairment: adjust therapy based on organ function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide plasma concentrations. - Octreotide or other somatostatin analogues: additive hormonal suppression can lead to excessive hormone inhibition. - Diazoxide: may diminish lanreotide’s therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: monitor blood glucose and adjust doses as needed. - Warfarin: observe INR values for potential anticoagulant effect changes. - Hormonal contraceptives: efficacy may be reduced; consider alternative contraception.